CCR3 antibody
GTX70769
ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetCCR3
Product GTX70769 is not available
Product not available
There may be an alternative product available, please contact our technical support team.
Overview
- SupplierGeneTex
- Product NameCCR3 antibody
- Delivery Days Customer9
- ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID1232
- Target nameCCR3
- Target descriptionC-C motif chemokine receptor 3
- Target synonymsb-chemokine receptor; C C CKR3; CC chemokine receptor 3; C-C chemokine receptor type 3; C-C CKR-3; CC-CKR-3; CCR-3; CD193; chemokine (C-C motif) receptor 3; CKR 3; CKR3; CMKBR3; eosinophil CC chemokine receptor 3; eosinophil eotaxin receptor
- HostRabbit
- IsotypeIgG
- Scientific DescriptionThe protein encoded by this gene is a receptor for C-C type chemokines. It belongs to family 1 of the G protein-coupled receptors. This receptor binds and responds to a variety of chemokines, including eotaxin (CCL11), eotaxin-3 (CCL26), MCP-3 (CCL7), MCP-4 (CCL13), and RANTES (CCL5). It is highly expressed in eosinophils and basophils, and is also detected in TH1 and TH2 cells, as well as in airway epithelial cells. This receptor may contribute to the accumulation and activation of eosinophils and other inflammatory cells in the allergic airway. It is also known to be an entry co-receptor for HIV-1. This gene and seven other chemokine receptor genes form a chemokine receptor gene cluster on the chromosomal region 3p21. Alternatively spliced transcript variants have been described. [provided by RefSeq, Sep 2009]
- ReactivityHuman
- Storage Instruction2°C to 8°C,-20°C or -80°C
- UNSPSC12352203
References
- Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. Sugasawa H et al., 2008 Apr 1, J Surg OncolRead more
- Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Sugasawa H et al., 2008 Jun 1, Int J CancerRead more